Amgen raises annual forecast: Growth medications like Repatha more than offset pressure from generics!

Amgen increases quarterly revenue by 8% to $10.4 billion, surpassing expectations for both revenue and profit. Strong growth from newer medications compensates for the decline in bone treatments Prolia and Xgeva. The biotech company therefore raises its targets for the entire year. Results exceed expectations In the third quarter of 2026, Amgen achieves a revenue of $10.37 billion, which is about 3% above the analyst estimate of $10.07 billion as reported by FactSet. The adjusted earnings per share rise by 14% to $6.45, exceeding the expected...